Pleiotrope Effekte Empagliflozins auf humanes und murines Myokard

Bollenberg, Hannah

dc.contributor.advisor	Sossalla, Samuel T. Prof. Dr.
dc.contributor.author	Bollenberg, Hannah
dc.date.accessioned	2025-07-14T17:31:14Z
dc.date.available	2025-08-13T00:50:09Z
dc.date.issued	2025-07-14
dc.identifier.uri	http://resolver.sub.uni-goettingen.de/purl?ediss-11858/16110
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-11372
dc.format.extent	105	de
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc	610	de
dc.title	Pleiotrope Effekte Empagliflozins auf humanes und murines Myokard	de
dc.type	doctoralThesis	de
dc.contributor.referee	Voigt, Niels Prof. Dr.
dc.date.examination	2025-07-16	de
dc.description.abstracteng	Heart failure with preserved ejection fraction (HFpEF) remains a clinical challenge with limited treatment options. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been shown to reduce cardiovascular mortality and hospitalization in heart failure patients, yet the underlying cardiac mechanisms remain incompletely understood. This dissertation investigates the direct, diabetes-independent effects of empagliflozin on myocardial function using both human and murine myocardial tissue. Human failing hearts and murine myocardial strips were analyzed ex vivo to assess systolic and diastolic parameters under empagliflozin treatment. The results demonstrated that empagliflozin significantly reduced diastolic tension without affecting systolic force development or calcium handling indicators. Notably, no significant differences were observed in post-rest behavior or force-frequency relationships compared to controls. These findings suggest that the beneficial effects of empagliflozin on diastolic function may occur independently of systemic metabolic changes, highlighting a novel therapeutic mechanism in the treatment of HFpEF. This work adds mechanistic insight to the EMPA-REG OUTCOME study and offers a rationale for further translational studies.	de
dc.contributor.coReferee	Schön, Margarete Prof. Dr.
dc.subject.eng	Empagliflozin	de
dc.subject.eng	SGLT-2-Inhibitors	de
dc.subject.eng	HFpEF	de
dc.subject.eng	Heart Failure	de
dc.subject.eng	myocardial contraction	de
dc.subject.eng	diastolic dysfunction	de
dc.subject.eng	EMPA-REG	de
dc.identifier.urn	urn:nbn:de:gbv:7-ediss-16110-9
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	Pharmakologie / Toxikologie / Pharmakotherapie - Allgemein- und Gesamtdarstellungen (PPN61987550X)	de
dc.description.embargoed	2025-08-13	de
dc.identifier.ppn	1930551908
dc.notes.confirmationsent	Confirmation sent 2025-07-14T19:45:01	de

Files in this item

Name:ohne Lebenslauf Dissertation Hannah Bollenberg Endversion 04-24.pdf

Size:3.855Mb

Format:PDF

View/Open

Name:: ohne Lebenslauf Dissertation ...
Size:: 3.855Mb
Format:: PDF

View/Open

This item appears in the following Collection(s)

Human- und Zahnmedizin [3404]

Show simple item record